Trial Profile
Drug Use-Results Survey of OPDIVO (all case surveillance) [recurrent or distant metastatic head and neck cancer]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 18 Oct 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2018 Status has been changed to active, no longer recruiting.
- 27 Aug 2018 New trial record